FUROSCIX furosemide injection 80 mg/ 10 mL 8 mg/mL Injection
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Loop Diuretic class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Furosemide is used alone or with other medications to treat high blood pressure. Furosemide is used to treat edema excess fluid held in body tissues caused by various medical problems. Furosemide is in a class of medications called diuretics ('water pills'). It works by causing the kidneys to get rid of unneeded water and salt from the body. High blood pressure is a common condition. When not treated, it can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. This damage may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vi...
Read the full MedlinePlus article ↗- Furosemide is a strong 'water pill' that tells your kidneys to flush out excess sodium and water through your urine. If your legs are swollen or you're short of breath from fluid b...
- Why did my doctor prescribe furosemide — what is it actually doing for me?
- Yes, that's exactly what furosemide is supposed to do. The whole point is to increase urine output so your body can shed excess fluid. Many people notice it kicks in within an hour...
- I'm going to the bathroom a lot more — is that normal?
Patient education
Supplement & herbal interactions
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | $958.70 | $958.70 / 1 cartridge |
| Medicare drug plans payPart D · Q2 2026 | $1,064.82 | $1,064.82 / 1 cartridge |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Furoscix 8 mg/mLthis 71767-0100-01 | scPharmaceuticals | 1 kit | — | — | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route. Patent/protection dates below may affect future generic timing.
Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.
🛈 What do these terms mean?
- Patent
- Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
- Substance patent
- Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
- Formulation (product) patent
- Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
- Method-of-use patent
- A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
- Skinny label
- A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
- Exclusivity
- FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
- Paragraph IV
- A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
- RLD / RS
- Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
- TE / AB rating
- FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
- LOE (loss of exclusivity)
- The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.
Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.
| Patent | Type | Use code | Expires |
|---|---|---|---|
| US 11433044 ↗ | Method of use | U-3462 | Apr 3, 2034 |
| US 9884039 ↗ | Method of use | U-3462 | Apr 3, 2034 |
| US 12370168 ↗ | Method of use | U-3462 | Apr 3, 2034 |
| US 10272064 ↗ | Drug product | — | Apr 3, 2034 |
Is there a generic version of FUROSCIX 80 MG/10ML ON-BODY KT?
The FDA approved a generic — why can’t I get it at my pharmacy yet?
Why do different websites show different generic release dates?
What does “FDA listed” mean?
What does a patent or protection date mean here?
What does “current Orange Book estimate” mean?
Can a generic come out before the last patent expires?
Can a generic come out after the listed dates?
What is the difference between patents and exclusivity?
Why are there multiple patent dates?
Where does this data come from?
🗺️ Medicaid utilization & spend
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 71767-0100-01 You're viewing this | 1 CARTON in 1 KIT (71767-100-01) / 1 CARTRIDGE in 1 CARTON / 10 mL in 1 CARTRIDGE | 2022-11-14 | Active |
🧭 About this NDC listing & data coverage
Kit / multi-component package
This NDC identifies a kit — a package containing more than one component. Structured data (pricing, ingredients, equivalents) is often reported per component rather than for the kit NDC itself, which can make this page look thinner than the components' own pages.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | ✓ Available |
Questions about this listing
Why is there no price listed?
Is the NDC printed on the package the same as the 11-digit billing NDC?
What do the three segments of this NDC mean?
Is this package still being marketed?
Who lists this product with the FDA?
Do I need a prescription for this product?
Where does this data come from?
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE FUROSCIX is indicated for the treatment of edema in pediatric patients weighing 43 kg and above and in adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome. FUROSCIX is a loop diuretic indicated for the treatment of edema in pediatric patients weighing 43 kg and above and in adult patients with chronic heart failure or chronic kidney disease, including the nephrotic syndrome. ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION FUROSCIX is not for chronic use and should be replaced with oral diuretics as soon as practical. ( 2.1 ) The FUROSCIX ReadyFlow™ is pre-filled to deliver 80 mg of furosemide subcutaneously in about 10 seconds. The single-use, On-body Infusor is pre-programmed to deliver 30 mg of furosemide subcutaneously over the first hour then 12.5 mg per hour for the subsequent 4 hours.
( 2.1 ) See Full Prescribing Information for important administration instructions. ( 2.2 )
2.1Recommended Dosage FUROSCIX is not for chronic use and should be replaced with oral diuretics as soon as practical. Adult Patients: FUROSCIX ReadyFlow: The FUROSCIX ReadyFlow is an autoinjector that delivers 80 mg of furosemide subcutaneously in about 10 seconds [see Clinical Pharmacology ( 12 )] . Adult and Pediatric Patients 43 kg and Above: On-body Infusor for FUROSCIX: The single-use, On-body Infusor with prefilled cartridge is pre-programmed to deliver 30 mg of furosemide subcutaneously over the first hour followed by 12.5 mg per hour for the subsequent 4 hours [see Use in Specific Populations ( 8.6 ) and Clinical Pharmacology ( 12 )].
2.2Important Administration Instructions Inspect the parenteral drug product through the autoinjector viewing window or the prefilled cartridge for the On-body Infusor prior to administration. FUROSCIX is a clear, colorless to slightly yellow solution. Do not use FUROSCIX if you see particles or the solution is discolored or cloudy [see Description ( 11 )] .
FUROSCIX is intended for administration to the abdomen only. For each subcutaneous administration, rotate the site on the abdomen. Refer to the Instructions for Use for additional information.
FUROSCIX ReadyFlow (Adult Patients) : Instruct patients to select and clean an injection site on the abdomen at least two inches away from the belly button (navel) and avoid skin that is irritated or broken and areas with scars or stretch marks. Pull the blue cap straight off the FUROSCIX ReadyFlow and then firmly push and hold against the skin until the yellow plunger rod stops moving and fills the viewing window, about 10 seconds. On-body Infusor for FUROSCIX (Adult and Pediatric Patients 43 kg and above) : The On-body Infusor for FUROSCIX is not compatible with use in an MRI setting.
The On-body Infusor for FUROSCIX is intended for use in a setting where the patient can limit their activity for the duration of administration [see Warnings and Precautions ( 5.5 )] . Load the prefilled cartridge of furosemide into the On-body Infusor and close the cartridge holder. Peel away the adhesive liner on the On-body Infusor and apply onto a clean, dry area of the abdomen between the top of the beltline and the bottom of the ribcage that is not tender, bruised, red or indurated.
The distance from the top of the beltline to the bottom of the ribcage should be at least 2 ½ inches. Start the injection by firmly pressing and releasing the blue start button. Do not remove until the injection is complete (signaled by the solid green status light, beeping sound, and the white plunger rod filling the cartridge window).
In pediatric patients weighing at least 43 kg, FUROSCIX On-body Infusor must be administered by a healthcare provider or adult caregiver. Adult patients or caregivers should receive proper instruction in preparing and administering FUROSCIX before using the FUROSCIX On-body Infusor.
2.1Recommended Dosage FUROSCIX is not for chronic use and should be replaced with oral diuretics as soon as practical. Adult Patients: FUROSCIX ReadyFlow: The FUROSCIX ReadyFlow is an autoinjector that delivers 80 mg of furosemide subcutaneously in about 10 seconds [see Clinical Pharmacology ( 12 )] . Adult and Pediatric Patients 43 kg and Above: On-body Infusor for FUROSCIX: The single-use, On-body Infusor with prefilled cartridge is pre-programmed to deliver 30 mg of furosemide subcutaneously over the first hour followed by 12.5 mg per hour for the subsequent 4 hours [see U…
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Injection : 80 mg/mL as a clear, colorless to slightly yellow solution in a single-dose prefilled autoinjector. 80 mg/10 mL (8 mg/mL) as a clear to slightly yellow solution in a single-dose prefilled cartridge for use only with co-packaged single-use, On-body Infusor. Injection: 80 mg/mL in a single-dose prefilled autoinjector ( 3 ) 80 mg/10 mL (8 mg/mL) in a single-dose prefilled cartridge co-packaged with a single-use On-body Infusor.
( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS FUROSCIX is contraindicated in: Patients with anuria. Patients with a history of hypersensitivity to furosemide, or any component of the FUROSCIX formulation. The On-body Infusor for FUROSCIX is contraindicated in patients with a history of hypersensitivity to medical adhesives Anuria ( 4 ) Hypersensitivity to furosemide, or components of FUROSCIX formulation ( 4 ) FUROSCIX On-body Infusor: Hypersensitivity to medical adhesives ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Fluid, Electrolyte, and Metabolic Abnormalities : Monitor serum electrolytes, CO 2 , BUN, creatinine, glucose, and uric acid. ( 5.1 ) Worsening Renal Function : Monitor for dehydration and azotemia. ( 5.2 ) Ototoxicity : Avoid higher than recommended doses.
( 5.3 , 7.1 ) Acute Urinary Retention : Monitor patients with symptoms of urinary retention. ( 5.4 ) Incomplete Dosing : Fluid contact and certain patient movements during treatment may cause the On-body Infusor to prematurely terminate infusion. Ensure the patient or caregiver can detect and respond to alarms.
( 5.5 )
5.1Fluid, Electrolyte, and Metabolic Abnormalities Furosemide may cause fluid, electrolyte, and metabolic abnormalities such as hypovolemia, hypokalemia, azotemia, hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypocalcemia, hyperglycemia, or hyperuricemia, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.
Serum electrolytes, CO 2 , BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy [see Use in Specific Populations ( 8.6 )] .
5.2Worsening Renal Function Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide [see Clinical Pharmacology ( 12.3 )].
5.3Ototoxicity Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high-dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used) [see Drug Interactions ( 7.1 )].
5.4Acute Urinary Retention In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment.
5.5Incomplete Dosing The FUROSCIX ReadyFlow should be held against the abdomen until the yellow plunger rod stops moving and fills the viewing window. This may take about 10 seconds. The On-body Infusor for FUROSCIX should not be allowed to get wet from water or any other fluids (blood or drug product).
Fluid contact with the circuit board can lead to device errors and premature termination of infusion. The On-body Infusor for FUROSCIX is intended for use in a setting where the patient can limit their activity for the duration of administration. Certain patient movements may cause interruption of device adherence to skin and premature termination of infusion.
The On-body Infusor for FUROSCIX should only be administered in settings where alarms can be detected and responded to in order to ensure a complete dose is administered [see Dosage and Administration ( 2.2 )] .
5.1Fluid, Electrolyte, and Metabolic Abnormalities Furosemide may cause fluid, electrolyte, and metabolic abnormalities such as hypovolemia, hypokalemia, azotemia, hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypocalcemia, hyperglycemia, or hyperuricemia, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, pa…
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following important adverse reactions are discussed elsewhere in the labeling: Fluid, Electrolyte, and Metabolic Abnormalities [see Warnings and Precautions ( 5.1 )]. Ototoxicity [see Warnings and Precautions ( 5.3 )] The following adverse reactions associated with the use of furosemide were identified in clinical trials or post-marketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably, or to establish a causal relationship to drug exposure.
Adverse reactions are categorized below by organ system and listed by decreasing severity. Gastrointestinal System Reactions : pancreatitis, jaundice (intrahepatic cholestatic jaundice), increased liver enzymes, anorexia, oral and gastric irritation, cramping, diarrhea, constipation, nausea, vomiting. Systemic Hypersensitivity Reactions : severe anaphylactic or anaphylactoid reactions (e.g., with shock), systemic vasculitis, interstitial nephritis, necrotizing angiitis.
Central Nervous System Reactions : tinnitus and hearing loss, paresthesias, vertigo, dizziness, headache, blurred vision, xanthopsia. Hematologic Reactions : aplastic anemia, thrombocytopenia, agranulocytosis, hemolytic anemia, leukopenia, anemia, eosinophilia. Dermatologic Hypersensitivity Reactions : toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, drug rash with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, exfoliative dermatitis, bullous pemphigoid, purpura, photosensitivity, rash.
Cardiovascular Reactions : orthostatic hypotension, increase in cholesterol and triglyceride serum levels. Administration Site and Skin Reactions : administration site erythema, bruising, edema, mass, pruritus, and pain. Other Reactions : glycosuria, muscle spasm, weakness, restlessness, urinary bladder spasm, thrombophlebitis, transient injection site pain following intramuscular injection, fever.
The most common adverse reactions during treatment with FUROSCIX were administration site and skin reactions: erythema, bruising, edema and pain. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact MannKind Corporation at 1-877-323-8505 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS Aminoglycoside antibiotics : Increased potential ototoxicity of the antibiotics. Avoid combination. ( 7.1 ) Ethacrynic acid : Risk of ototoxicity.
Avoid combination ( 7.1 ) Salicylates : Risk of salicylate toxicity. ( 7.1 ) Cisplatin and nephrotoxic drugs : Risk of ototoxicity and nephrotoxicity. ( 7.1 ) Lithium : Risk of lithium toxicity.
( 7.1 ) Renin-angiotensin inhibitors : Increased risk of hypotension and renal failure. ( 7.1 ) Adrenergic blocking drugs : Risk of potentiation. ( 7.1 ) Drugs undergoing renal tubular secretion : Risk of toxicity potentiation.
( 7.1 ) See 17 for PATIENT COUNSELING INFORMATION .
7.1Effects of Furosemide on Other Drugs Drug/Substance Class or Name Drug Interaction Effect Recommendations Aminoglycoside antibiotics Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function [see Warnings and Precautions ( 5.3 )]. Avoid combination except in life-threatening situations. Ethacrynic acid Possibility of ototoxicity [see Warnings and Precautions ( 5.3 )].
Avoid concomitant use with ethacrynic acid. Salicylates May experience salicylate toxicity at lower doses because of competitive renal excretory sites. Monitor for symptoms of salicylate toxicity.
Cisplatin There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly [see Warnings and Precautions ( 5.3 )]. Administer furosemide at lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment. Monitor renal function.
Cisplatin and nephrotoxic drugs Nephrotoxicity Paralytic agents Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine. Monitor for skeletal muscle effect. Lithium Furosemide reduces lithium’s renal clearance and add a high-risk of lithium toxicity.
Avoid concomitant use with lithium. Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers May lead to severe hypotension and deterioration in renal function, including renal failure. Monitor for changes in blood pressure and renal function and interrupt or reduce the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers if needed.
Antihypertensive drugs Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs. Monitor for changes in blood pressure and adjust the dose of other antihypertensive drugs if needed. Adrenergic blocking drugs or peripheral adrenergic blocking drugs Potentiation occurs.
Monitor for changes in blood pressure and adjust the dose of adrenergic blocking drugs if needed. Norepinephrine Furosemide may decrease arterial responsiveness (vasoconstricting effect) to norepinephrine. Monitor blood pressure (or mean arterial pressure).
Chloral hydrate In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia. Concomitant use with chloral hydrate is not recommended. Methotrexate and other drugs undergoing renal tubular secretion Furosemide may decrease renal elimination of other drugs that undergo tubular secretion.
High-dose treatment of furosemide may result in elevated serum levels of these drugs and may potentiate their toxicity. Monitor serum levels of drugs undergoing renal tubular secretion and adjust the dose if needed. Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment.
Monitor for changes in renal function. Cyclosporine Increased risk of gouty arthritis secondary to furosemide-induced hyperuricemia and cyclosporine impairment of renal urate excretion. Monitor serum urate levels.
Thyroid hormones High-doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier p…
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary Available data from published observational studies, case reports, and post marketing reports, from decades of use, have not demonstrated a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes with furosemide use during pregnancy. Untreated congestive heart failure and cirrhosis of the liver can lead to adverse outcomes for the mother and the fetus (see Clinical Considerations). In animal reproduction studies, furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits when administered orally during organogenesis at 4 times a human i.v. dose of 80 mg based on body surface area (BSA) and oral bioavailability corrections, presumably secondary to volume depletion (see Data).
FUROSCIX ReadyFlow contains benzyl alcohol (BA) as a preservative. Because BA is rapidly metabolized by a pregnant female, BA exposure in the fetus is unlikely. The estimated background risk for major birth defects and miscarriage for the indicated populations is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo/fetal Risk Pregnant women with congestive heart failure are at increased risk for pre-term birth.
Stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. Clinical classification of heart disease may worsen with pregnancy and lead to maternal death and/or stillbirth. Closely monitor pregnant patients for destabilization of their heart failure.
Pregnant women with symptomatic cirrhosis generally have poor outcomes including hepatic failure, variceal hemorrhage, pre-term delivery, fetal growth restriction and maternal death. Outcomes are worse with coexisting esophageal varices. Carefully monitor pregnant women with cirrhosis of the liver.
Data Animal Data The effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats, and rabbits. Furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest dose of 25 mg/kg (approximately 4 times the human i.v. dose of 80 mg based on BSA and oral bioavailability corrections). In another study, a dose of 50 mg/kg (approximately 7 times a human i.v. dose of 80 mg based on BSA and oral bioavailability corrections) also caused maternal deaths and abortions when administered to rabbits between Days 12 and 17 of gestation.
In a third study, none of the pregnant rabbits survived an oral dose of 100 mg/kg. Data from the above studies indicate fetal lethality that can precede maternal deaths. The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses of treated dams as compared with the incidence of fetuses from the control group.
8.2Lactation Risk Summary The presence of furosemide has been reported in human breast milk. There are no data on the effects on the breastfed infant or the effects on milk production. Doses of furosemide associated with clinically significant diuresis may impair milk production.
FUROSCIX ReadyFlow contains benzyl alcohol (BA) as a preservative. Because BA is rapidly metabolized by a pregnant female, BA exposure in the breastfed neonate is unlikely. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for furosemide and any potential adverse effects on the breastfed infant from furosemide or from the underlying maternal condition.
8.4Pediatric Use Safety and efficacy of the FUROSCIX ReadyFlow for pediatric use have not been establi…
🆘 Overdosage ▾
10 OVERDOSAGE The principal signs and symptoms of overdose with FUROSCIX are dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia and hypochloremic alkalosis, and are extensions of its diuretic action. The concentration of furosemide in biological fluids associated with toxicity or death is not known. Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses.
Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy). Hemodialysis does not accelerate furosemide elimination.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone.
12.2Pharmacodynamics In healthy adults, subcutaneous administration of FUROSCIX (80 mg furosemide injection via the ReadyFlow) produced similar diuresis, natriuresis, and kaliuresis to intravenous administration (two 40 mg bolus doses separated by 120 minutes) at 6, 8, and 12 hours post-dose. The duration of diuretic effect with FUROSCIX ReadyFlow was up to 6 hours after initiation of dosing. In adult patients with NYHA Class II and Class III heart failure, subcutaneous administration of FUROSCIX (30 mg furosemide over the first hour followed by 12.5 mg per hour for the subsequent 4 hours, total 80 mg furosemide) produced similar diuresis and natriuresis to intravenous administration (two 40 mg bolus doses separated by 120 minutes) at 8 and 24 hours post-dose.
The duration of diuretic effect with FUROSCIX On-body Infusor was up to 8 hours after initiation of dosing.
12.3Pharmacokinetics Absorption In healthy adults, subcutaneous injection of FUROSCIX (80 mg furosemide injection via the ReadyFlow), the bioavailability was 107.3% (90% CI: 103.9, 110.8) relative to 80 mg intravenous furosemide (two 40‑mg bolus doses separated by 120 minutes) with a median (min-max) T max of 0.75 (0.5-1.5) hours. The pharmacokinetic parameters of FUROSCIX following subcutaneous injection via the ReadyFlow autoinjector are presented in Table 1 below: Table 1: Pharmacokinetic Data of FUROSCIX Following Subcutaneous Injection via the ReadyFlow Autoinjector (n = 19) Dose C max (ng/mL) AUC t (ng×hr/mL) T 1/2 (hr) AUC ∞ (ng×hr/mL) FUROSCIX: 80 mg injection via the ReadyFlow 4,530 ± 1,500 12,500 ± 4,010 2.2 ± 0.3 12,700 ± 4,120 Furosemide administered as 2 x 40 mg bolus doses intravenously, separated by 120 minutes (total dose: 80 mg furosemide) 10,100 ± 2,810 11,700 ± 3,450 1.9 ± 0.4 11,800 ± 3,510 In adult patients with NYHA Class II-III congestive heart failure, subcutaneous infusion of FUROSCIX (30 mg furosemide over the first hour followed by 12.5 mg per hour for the subsequent 4 hours, 80 mg furosemide total), the bioavailability was 99.6% (90% CI: 94.8, 104.8) relative to 80 mg intravenous furosemide (two 40-mg bolus doses separated by 120 minutes) with a median T max (min-max) of 4 (1.00 - 5.08) hours.
The pharmacokinetic parameters of FUROSCIX following subcutaneous infusion via the On-body Infusor are presented in Table 2 below: Table 2: Pharmacokinetic Data of FUROSCIX Following Subcutaneous Infusion via the On-body Infusor (n = 15) Dose Cmax (ng/mL) AUCt (ng×hr/mL) T1/2 (hr) AUC∞ (ng×hr/mL) FUROSCIX: 30 mg subcutaneously infused over the first hour followed by 12.5 mg per hour for the subsequent 4 hours (total dose: 80 mg furosemide) 2,040 ± 449 13,000 ± 4,000 3.2 ± 0.9 13,100 ± 4,010 Furosemide administered as 2 x 40 mg bolus doses intravenously, separated by 120 minutes (total dose: 80 mg furosemide) 8,580 ± 2,540 13,000 ± 4,050 2.6 ± 0.3 13,200 ± 4,170 The impact of subcutaneous edema at the administration site of FUROSCIX on drug absorption is unknown.
Distribution Furosemide is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 mcg per mL to 400 mcg per mL are 91% to 99% bound in healthy individuals. The unbound fraction averages 2.3% to 4.1% at therapeutic concentrations.
Elimination The terminal half-life of furosemide is approximately 2 hours. Metabolism Furosemide glucuronide is the only or at least the major biotransformation product of furosemide in humans. Excretion Significantly more furosemide is excreted in urine following the intravenous injection than after the tablet or oral solution.
Specific Populations Pediatric Patient…
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING FUROSCIX injection is a sterile, clear, colorless to slightly yellow, non-pyrogenic liquid supplied either in a single-dose autoinjector for subcutaneous injection or in a single-dose prefilled cartridge for subcutaneous infusion co-packaged with the On-body Infusor. Carton containing one 80 mg/mL single-dose prefilled autoinjector NDC 71767-111-01 Carton containing one 80 mg/10 mL (8 mg/mL) prefilled cartridge co-packaged with one On-body Infusor NDC 71767-100-01 Store between 20°C and 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature].
Do not refrigerate or freeze. Protect from light. Do not remove the FUROSCIX ReadyFlow or cartridge for use in the On-body Infusor from carton until it is ready for use.
Do not use if you see particles in the solution or if the solution is discolored or cloudy. Protect the On-body Infusor for FUROSCIX from water.
📋 Description ▾
11 DESCRIPTION FUROSCIX (furosemide injection 80 mg/10 mL or 80 mg/mL) is a loop diuretic which is an anthranilic acid derivative. Chemically, it is 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid. Furosemide is a white to slightly yellow crystalline powder.
It is sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids. The structural formula is as follows: Molecular Formula: C 12 H 11 ClN 2 O 5 S Molecular Weight: 330.75 g/mol FUROSCIX ReadyFlow : The ReadyFlow is a disposable, fixed single-dose, mechanical spring driven autoinjector. The ReadyFlow is preloaded with the prefilled syringe containing the drug and delivers 80 mg of furosemide in about 10 seconds.
The single-dose prefilled FUROSCIX ReadyFlow contains 80 mg per 1 mL sterile, clear, colorless to slightly yellow, and non-pyrogenic furosemide solution. The pH of FUROSCIX for administration via the ReadyFlow, 7.7, differs from that of Furosemide Injection, USP. Autoinjector contains 1 mL of FUROSCIX ReadyFlow that contains 80 mg furosemide and the following inactive ingredients: benzyl alcohol (35 mg), hydrochloric acid for pH adjustment if needed, sodium hydroxide for pH adjustment if needed, tromethamine (9.7 mg), and water for injection (q.s.).
On-body Infusor for FUROSCIX : The On-body Infusor for FUROSCIX is a wearable, single-use, electromechanical (battery powered, micro-processor controlled), on-body delivery system that is pre-programmed to deliver 80 mg of furosemide over 5-hours using a bi-phasic delivery profile. FUROSCIX for administration via the On-body Infusor is provided in a single-dose prefilled cartridge co-packaged with a single-use, On-body Infusor. The single-dose prefilled cartridge contains 80 mg per 10 mL sterile, clear, colorless to slightly yellow, and non-pyrogenic furosemide solution.
The pH of FUROSCIX for administration via the On-body Infusor, 7.4, differs from that of Furosemide Injection, USP. Each 1 mL of FUROSCIX for administration via the On-body Infusor contains the following inactive ingredients: hydrochloric acid for pH adjustment if needed, sodium chloride (5.84 mg), sodium hydroxide for pH adjustment if needed, tris HCl (7.88 mg), and water for injection (q.s.). Structure